ArticleMedical oncology (Northwood, London, England)2025
Exploring the anticancer potential of R. tridentata extracts: a cytotoxicity study against human prostate cancer cell lines (LNCaP and DU145).
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Solvent-Based Extraction Recovers Phytochemicals from Medicinal Plants Demonstrating Anticancer and Chemopreventive Potential: A Review.Molecules (Basel, Switzerland) · 2026Review
- Sub-acute toxicity profiles of Rhoicissus tridentata as used in the traditional prostate cancer managment in the Elgon in Wistar albino rats.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the cytotoxic effects of R. tridentata extracts on prostate cancer cells, providing insight into its potential therapeutic benefits and scientific validation for its traditional use in cancer treatment. The cytotoxicity of R. tridentata extracts was evaluated on prostate cancer cell lines (LNCaP and DU 145) using the MTT assay, with doxorubicin as a reference standard. Our findings demonstrated significant concentration- and time-dependent cytotoxic effects of the extracts on both cell lines (p < 0.0024 to p < 0.0002). Notably, the methanol extract exhibited potent cytotoxicity, with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.